Studies from 2016 on psilocybin, an alkaloid from the psychedelic family, have shown that it relieves the symptoms of depression- benefits that are obtained quickly, with only 2-3 microdoses, and are maintained for several months.
Thanks to these findings, the FDA granted, in 2019, the status of “revolutionary therapy” for psilocybin in the treatment of major depressive disorders and decided to begin intensive clinical trials in this direction.
The immediate and lasting growth of connections between neurons, as a consequence of psilocybin microdosing, is efficient and lasting, which may open a new era in the medical use of psychedelic drugs.
Psilocybin and psilocin are controlled internationally, at the highest level, but in some countries there have been uncertainties in establishing the legal status of mushrooms containing such substances. This confusion has been exploited by mushroom sellers, hindering the development of supply control mechanisms.
In the US, the status of magical mushroom spores is different from the status of psilocybin mushrooms, and that’s because spores do not contain psilocybin. This substance is only contained within mycelium and mature mushrooms. That’s why a Psilocybe Cubensis high concentration spore syringe can be purchased legally in most of the states, as long as they are used for research and studying.